Advertisement

Pharmacokinetics of [125I]-recombinant human interleukin-11: 1. Absorption, distribution and excretion after subcutaneous administration to male rats

  • T. Uchida
  • K. Aoyama
  • K. Mori
  • T. Usui
  • T. Watanabe
  • Y. Takariki
  • N. Asahara
  • M. Hirose
  • T. Kimura
  • M. Tateishi
  • S. Higuchi
Article

Summary

Absorption, distribution, metabolism and excretion of [125I]-rhIL-11 (recombinant human interleukin-11) after subcutaneous administration in rats were investigated. After a single administration, the concentration of radioactivity in the tissues was 2–6-fold higher in the liver and kidneys, and slightly higher in the gastrointestinal tract as compared to the plasma concentration. However, since the concentration in the other tissues was lower than the plasma concentration, the transport of rhIL-11 into tissues appeared to be low. Tissue radioactivity rapidly diminished, thus accumulation of rhIL-11 in tissues was thought to be low. Excretion of radioactivity into urine and feces was almost complete 72 h after administration, with 88.5% of the dosed radioactivity being found in urine and 7.9% in feces. When [125I]-rhIL-11 was administered to bile-duct cannulated rats, 44.4% of the dosed radioactivity was excreted into bile up to 48 h after administration. Most radioactivity in bile and urine was found in the TCA supernatant and low molecular weight fraction by HPLC analysis, indicating that rhIL-11 was eliminated from the body by metabolism.

Keywords

Recombinant human interleukin-11 subcutaneous administration absorption metabolism disposition 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Paul S.R., Bennett F., Calvetti J.A. et al. (1990): Molecular cloning of a cDNA encoding interleukin 11, a stromal cell-derived lymphopoietic and hematopoietic cytokine. Proc. Natl. Acad. Sci. USA, 87, 7512–7516.CrossRefPubMedGoogle Scholar
  2. 2.
    Yonemura Y., Kawakita M., Masuda T., Fujimoto K., Kato K., Takatsuki K. (1992): Synergistic effects of interleukin 3 and interleukin 11 on murine megakaryopoiesis in serum-free culture. Exp. Hematol., 20, 1011–1016.PubMedGoogle Scholar
  3. 3.
    Teramura M., Kobayashi S., Hoshino S., Oshime K., Mizoguchi H. (1992): Interleukin-11 enhances human megakaryocytopoiesis in vitro. Blood, 79, 327–331.PubMedGoogle Scholar
  4. 4.
    Neben T.Y., Loebelenz J., Hayes L. et al. (1993): Recombinant human interleukin-11 stimulates megakaryocytopoietisis and increases peripheral platelets in normal and splenectomized mice. Blood, 81, 901–908.PubMedGoogle Scholar
  5. 5.
    Leonard J.P., Quinto C.M., Kozitza M.K., Neben T.Y., Goldman S.J. (1994): Recombinant human interleukin-11 stimulates multilineage hematopoietic recovery in mice after a myelosuppressive regiment of sublethal irradiation and carboplatin. Blood, 83, 1499–1506.PubMedGoogle Scholar
  6. 6.
    Kawashima I., Takiguchi Y. (1992): Interleukin-11: a novel stroma-derived cytokine. Prog. Growth Factor Res., 4, 191–206.CrossRefPubMedGoogle Scholar
  7. 7.
    Yin T., Miyazawa K., Yang Y. (1992): Characterization of interleukin-11 receptor and protein tyrosine phosphorylation induced by interleukin-11 in mouse 3T3-L1 cells. J. Biol. Chem., 267, 8347–8351.PubMedGoogle Scholar
  8. 8.
    Takagi A., Masuda H., Takakura Y., Hashida M. (1995): Disposition characteristics of recombinant human interleukin-11 after a bolus intravenous administration in mice. J. Pharmacol. Exp. Ther., 275, 537–545.PubMedGoogle Scholar
  9. 9.
    Takagi A., Yabe Y., Oka Y., Sawai K., Takakura Y., Hashida M. (1996): Renal disposition of recombinant human interleukin-11 in the isolated perfused rat kidney. Pharm. Res., 14, 86–90.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag 1998

Authors and Affiliations

  • T. Uchida
    • 1
  • K. Aoyama
    • 1
  • K. Mori
    • 1
  • T. Usui
    • 1
  • T. Watanabe
    • 1
  • Y. Takariki
    • 2
  • N. Asahara
    • 2
  • M. Hirose
    • 2
  • T. Kimura
    • 2
  • M. Tateishi
    • 2
  • S. Higuchi
    • 1
  1. 1.Drug Metabolism LaboratoriesYamanouchi Pharmaceutical Co. LtdTokyoJapan
  2. 2.Tsukuba Laboratory, Life Science LaboratoryNemoto & Co., LtdMitsukaido, IbarakiJapan

Personalised recommendations